Study of IMM0306 for IgG4-related disease
Part of Immune system & allergy clinical trials.
This trial is testing a new investigational drug called IMM0306 for people with IgG4-related disease, a condition where the body's immune system attacks its own organs. If you're currently needing steroids for a flare, this study might offer a new treatment option that could help control the disease with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with IgG4-related disease (IgG4-RD), a condition that causes swelling and damage in certain organs.
- Your disease has affected at least two different organs or sites in your body during its course.
- You need to start or continue steroid treatment (like prednisone) for a recent flare-up of your disease.
- Your current flare should not be only fibrosis (scar-like changes) — other active symptoms are acceptable.
- You must not have other active immune diseases requiring long-term immunosuppressants, active infections, or recent treatment with certain immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug, ACE1831, in people with active IgG4-related disease (IgG4-RD), a condition where the immune system causes inflammation and swelling in organs. The purpose is to see if ACE1831 is safe and effective in reducing disease flare-ups, possibly offering a new treatment option.
This trial tests a drug called sirolimus (which helps calm the immune system) for people with active IgG4-related disease. It may help reduce symptoms like swelling and pain if your current treatments are not working well.
This trial tests a new treatment called BCT301 for people with IgG4-related disease (an autoimmune condition causing swelling in organs like the pancreas or kidneys) that has not improved with standard treatments. The therapy targets certain immune cells to help reduce disease activity.
This is a study that follows people diagnosed with IgG4-related disease to better understand the condition. It may help researchers confirm diagnoses and learn how the disease affects different organs over time.
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
This study tests a drug called lenalidomide to see if it can help control active IgG4-related disease, a condition that causes inflammation and swelling in organs. The drug is taken by mouth, and the study compares it to a placebo (a pill with no medicine).
Hear when a new IgG4-Related Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.